Q3 2024 Management View Revenue for Q3 FY2024 increased 16.6% year-on-year to ¥1,367.6 billion, driven by growth in oncology ...

Japanese drugmaker Daiichi Sankyo has appointed Hiroyuki Okuzawa to succeed Sunao Manabe, as chief executive (CEO), effective April 1, 2025.

Daiichi Sankyo appoints Hiroyuki Okuzawa as chief executive officer: Tokyo Saturday, February 1, 2025, 12:30 Hrs [IST] ...

Basel: Roche has announced that the U.S. Food and Drug Administration (FDA) has approved a label expansion for the PATHWAY ...

US President Donald Trump announced plans to impose tariffs on imported computer chips pharmaceuticals and steel aiming to ...

Roche’s PATHWAY HER2 (4B5) test helps identify patients with HER2-ultralow breast cancer, who may be eligible for targeted ...

Daiichi Sankyo’s Vanflyta has become the first drug in the US to be approved for newly-diagnosed acute myeloid leukaemia (AML) with FLT3-ITD mutations, nearly four years after being rejected by ...

AbbVie stock retook its 200-day moving average Friday after the company raised its long-term outlook for Skyrizi and Rinvoq ...

U.S. President Donald Trump announced plans to impose tariffs on imported computer chips, pharmaceuticals, and steel, aiming to drive more manufacturing within the United States ...

The current price of Dai (DAI) is $0.999971, as of January 31, 2025. Over the last 24 hours, the price has moved by 0%, with a change of 0.05% in the past hour. For longer-term performance, the price ...